Inhibitor Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
Inhibitor Therapeutics provided an update on its itraconazole program for Gorlin Syndrome, detailing clinical progress, formulation strategy, and plans for a new global patent filing.
OQB
Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor for a $3 million private placement, issuing common stock and warrants.
OQB
Inhibitor Therapeutics, Inc. entered into a master services agreement with Frameshift Management for biostatistics and regulatory consulting and approved its 2025 Equity Incentive Plan, reserving 20 million shares.